AMA Journal of Ethics

Since the 1960s, drug names have been products of complex, multiparty negotiations in which interests of patients, pharmaceutical firms, clinicians, and US and international regulators must be balanced.

Ethics questions arise about the usefulness of a system that pegs Medicaid drug spending to net prices negotiated by others in the market.

Case-based teaching, longitudinal application, and training in ethical deliberation can better prepare physicians to responsibly prescribe and manage opioids.

This graphic narrative considers the shortage of normal saline in US health care organizations after Hurricane Maria devastated Puerto Rico in 2017.

Medications now challenge clinicians to consider market influences such as pharmaceutical manufacturing, pricing strategies, and patients’ resources.

Advances in CEA methodology might integrate equity at the cost of transparency.

In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013.

The AMA Code of Medical Ethics offers guidance on stewardship and professionalism.

This collection of drawings offers a visual exploration of compassion, respect, and dignity in clinical relationships and encounters.

Louisiana has a subscription model for hepatitis C treatment, but costly medications challenge states’ capacities to cover patients.